Eli Lilly and Boehringer Ingelheim secured approval from the US Food and Drug Administration (FDA) to expand the indications of its diabetes drug Jardience. The new indications include children under 10 with type 2 diabetes, a growing population in recent years. The drug would be the first in its class for patients in this age group, opening up a new avenue for early life diabetes management.
Shortly after receiving the nod from the US Food and Drug Administration (FDA), Vertex Pharma announced that it will soon bring its new application of its diabetes cell therapy to clinics by summer of this year. The therapy uses a special delivery method that removes the need for immune suppressants after delivering stem cells that can restore the function of insulin-producing pancreatic cells.
In a talk at the Morgan Stanley healthcare conference this week, Eli Lilly’s CFO Anat Ashkenazi spoke about the company’s deliberations in deciding whether to split Tirzepatide into two brands, one for diabetes and one for obesity. Lilly has done this before with Prozac (fluoxetine), making a new brand for premenstrual dysphoric disorder. It did not do the same for the drug Cialis, an erectile dysfunction drug also indicated for benign prostatic hyperplasia.
Continuous glucose monitoring is associated with better outcomes for people living with diabetes. Unfortunately, this technology is not accessible to many patients, worsening outcomes for marginalized. In a newly published article in AJMC, the barriers to continuous glucose monitoring are laid out and ways to address these disparities are put forward. The role of insurance is highlighted.
A paper published in the journal eClinical Medicine explores the scope of illnesses patients in Europe with type II diabetes face. The study, which pulled data from around 224,000 patients with diabetes from North-West London, found that patients were most likely to present with one or more of five conditions when diagnosed as diabetic. The data came from the Discovery-NOW data set, which contains electronic health records (EHR) data from 2.5 million patients.
See how Veradigm, a business unit of Allscripts focused on generating data-driven healthcare insights using EHR data applied artificial intelligence to EHRs to improve therapeutic management of patients with concordant comorbidities who are living with type 2 diabetes.